Clene Inc. (NASDAQ:CLNN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $34.00.
A number of research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of Clene in a report on Monday, October 19th. Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th.
View Our Latest Stock Analysis on Clene
Clene Stock Performance
NASDAQ CLNN opened at $3.88 on Friday. Clene has a twelve month low of $3.02 and a twelve month high of $13.50. The stock has a market cap of $50.40 million, a price-to-earnings ratio of -1.11 and a beta of 0.91. The firm’s 50 day moving average price is $3.97 and its two-hundred day moving average price is $5.28.
Clene (NASDAQ:CLNN – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.06 million. On average, research analysts forecast that Clene will post -1.70 EPS for the current fiscal year.
Clene Company Profile
Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.
Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.
See Also
- Five stocks we like better than Clene
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
